X T L Biopharmaceuticals Ltd
XTLB0.784USD
+0.003+0.37%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
6.91MMarket Cap
LossP/E TTM
More Details of X T L Biopharmaceuticals Ltd Company
X T L Biopharmaceuticals Ltd (Xenograft Technologies Ltd) is an Israel-based biopharmaceutical company engaged in acquisition and development of pharmaceutical drugs for treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
X T L Biopharmaceuticals Ltd Info
Ticker SymbolXTLB
Company nameX T L Biopharmaceuticals Ltd
IPO dateSep 01, 2000
CEOBand (Noam)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endSep 01
Address5 Badner St., P.O.Box 8241
CityRAMAT GAN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code5218102
Phone97299557080
Websitehttps://www.xtlbio.com/
Ticker SymbolXTLB
IPO dateSep 01, 2000
CEOBand (Noam)
Company Executives of X T L Biopharmaceuticals Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Alexander Rabinovitch
Mr. Alexander Rabinovitch
Non-Executive Director
Non-Executive Director
1.46M
+120.96%
Mr. Doron Turgeman
Mr. Doron Turgeman
Non-Executive Director
Non-Executive Director
3.40K
--
Ms. Osnat Hillel Fain
Ms. Osnat Hillel Fain
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Dobroslav Melamed
Dr. Dobroslav Melamed
Non-Executive Director
Non-Executive Director
--
--
Dr. Jonathan Schapiro
Dr. Jonathan Schapiro
Non-Executive Director
Non-Executive Director
--
--
Mr. Shlomo Shalev
Mr. Shlomo Shalev
Chairman of the Board
Chairman of the Board
--
--
Mr. Itay Weinstein
Mr. Itay Weinstein
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Noam Band
Mr. Noam Band
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Iris Shapira Yalon
Ms. Iris Shapira Yalon
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Alexander Rabinovitch
Mr. Alexander Rabinovitch
Non-Executive Director
Non-Executive Director
1.46M
+120.96%
Mr. Doron Turgeman
Mr. Doron Turgeman
Non-Executive Director
Non-Executive Director
3.40K
--
Ms. Osnat Hillel Fain
Ms. Osnat Hillel Fain
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Dobroslav Melamed
Dr. Dobroslav Melamed
Non-Executive Director
Non-Executive Director
--
--
Dr. Jonathan Schapiro
Dr. Jonathan Schapiro
Non-Executive Director
Non-Executive Director
--
--
Mr. Shlomo Shalev
Mr. Shlomo Shalev
Chairman of the Board
Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, May 24
Updated: Sat, May 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rabinovitch (Alexander)
15.44%
Klinger (Roy)
9.11%
Klinger (Tal)
9.11%
Yaacobi (Yaron)
4.76%
Noked Capital Ltd.
2.10%
Other
59.47%
Shareholders
Shareholders
Proportion
Rabinovitch (Alexander)
15.44%
Klinger (Roy)
9.11%
Klinger (Tal)
9.11%
Yaacobi (Yaron)
4.76%
Noked Capital Ltd.
2.10%
Other
59.47%
Shareholder Types
Shareholders
Proportion
Individual Investor
41.29%
Hedge Fund
2.26%
Investment Advisor
0.20%
Research Firm
0.11%
Investment Advisor/Hedge Fund
0.10%
Other
56.03%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
8
237.40K
2.69%
-26.61K
2025Q2
13
3.90M
44.21%
+2.99M
2025Q1
10
922.00K
15.09%
+12.66K
2024Q4
10
901.89K
7.19%
-26.55K
2024Q3
10
905.55K
7.22%
-28.65K
2024Q2
11
926.75K
10.11%
-11.55K
2024Q1
10
932.64K
17.12%
+14.27K
2023Q4
11
912.91K
16.75%
-29.56K
2023Q3
11
913.58K
16.77%
-42.08K
2023Q2
12
913.96K
16.77%
-54.07K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rabinovitch (Alexander)
1.46M
16.58%
+800.00K
+120.96%
Apr 30, 2025
Klinger (Roy)
862.29K
9.78%
+862.29K
--
Apr 30, 2025
Klinger (Tal)
862.29K
9.78%
+862.29K
--
Apr 30, 2025
Yaacobi (Yaron)
450.00K
5.11%
+450.00K
--
Apr 30, 2025
Noked Capital Ltd.
198.89K
2.26%
--
--
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
17.26K
0.2%
+6.31K
+57.58%
Jun 30, 2025
Morgan Stanley & Co. LLC
11.01K
0.12%
-2.24K
-16.90%
Jun 30, 2025
Geode Capital Management, L.L.C.
8.90K
0.1%
--
--
Aug 31, 2025
Turgeman (Doron)
3.40K
0.04%
--
--
Apr 30, 2025
UBS Financial Services, Inc.
1.34K
0.02%
+1.34K
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 08, 2025
Merger
4→1
Date
Type
Ratio
Dec 08, 2025
Merger
4→1
FAQs
Who are the top five shareholders of X T L Biopharmaceuticals Ltd?
The top five shareholders of X T L Biopharmaceuticals Ltd are:
Rabinovitch (Alexander) holds 1.46M shares, accounting for 16.58% of the total shares.
Klinger (Roy) holds 862.29K shares, accounting for 9.78% of the total shares.
Klinger (Tal) holds 862.29K shares, accounting for 9.78% of the total shares.
Yaacobi (Yaron) holds 450.00K shares, accounting for 5.11% of the total shares.
Noked Capital Ltd. holds 198.89K shares, accounting for 2.26% of the total shares.
Rabinovitch (Alexander) holds 1.46M shares, accounting for 16.58% of the total shares.
Klinger (Roy) holds 862.29K shares, accounting for 9.78% of the total shares.
Klinger (Tal) holds 862.29K shares, accounting for 9.78% of the total shares.
Yaacobi (Yaron) holds 450.00K shares, accounting for 5.11% of the total shares.
Noked Capital Ltd. holds 198.89K shares, accounting for 2.26% of the total shares.
What are the top three shareholder types of X T L Biopharmaceuticals Ltd?
The top three shareholder types of X T L Biopharmaceuticals Ltd are:
Rabinovitch (Alexander)
Klinger (Roy)
Klinger (Tal)
Rabinovitch (Alexander)
Klinger (Roy)
Klinger (Tal)
How many institutions hold shares of X T L Biopharmaceuticals Ltd (XTLB)?
As of 2025Q3, 8 institutions hold shares of X T L Biopharmaceuticals Ltd, with a combined market value of approximately 237.40K, accounting for 2.69% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -41.52%.
What is the biggest source of revenue for X T L Biopharmaceuticals Ltd?
In --, the -- business generated the highest revenue for X T L Biopharmaceuticals Ltd, amounting to -- and accounting for --% of total revenue.
